Indoco Remedies Ltd
Indoco Remedies Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Indoco Remedies Ltd Q2 FY27 key numbers
- Revenue
- Consolidated revenues for Q2 FY 2026-27 are ₹5,069 million, up 7.4% year-on-year (YoY) from ₹4,718 million in the same quarter last year.
As stated in Indoco Remedies Ltd's Q2 FY27 results statement · published 27 Oct 2026. Reported figures, not investment advice.
Based on Indoco Remedies Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Consolidated revenues for Q2 FY 2026-27 are ₹5,069 million, up 7.4% year-on-year (YoY) from ₹4,718 million in the same quarter last year. Quarter ended 30.09.2026: - However, Revenue from Operations is ₹50,692 Lakhs and Expenses total ₹53,509 Lakhs, indicating an operating loss.
From Indoco Remedies Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.
Revenue & Sales Performance
- Consolidated revenues for Q2 FY 2026-27 are ₹5,069 million, up 7.4% year-on-year (YoY) from ₹4,718 million in the same quarter last year.
- EBIDTA margin for the quarter is 9.2% (₹464 million), slightly higher than 9.1% (₹431 million) in Q2 last year.
- For H1 FY 2026-27, consolidated revenues are ₹9,731 million, a 7.8% increase YoY from ₹9,027 million.
- Key business segments reported strong growth in Q2/H1:
- Regulated international formulations business grew +21.1% in Q2.
2 more points from Indoco Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
- Quarter ended 30.09.2026:
- However, Revenue from Operations is ₹50,692 Lakhs and Expenses total ₹53,509 Lakhs, indicating an operating loss.
- Profit After Tax (PAT): ₹1,947 Lakhs (profit for the period)
- Year-on-Year (YoY) change:
- PAT improved from a loss of ₹924 Lakhs in the quarter ended 30.09.2025 to a profit of ₹1,947 Lakhs.
2 more points from Indoco Remedies Ltd's call on margins
Create a free account to keep reading this call
Capital Expenditure Plans
See what Indoco Remedies Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indoco Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Indoco Remedies Ltd said on order book & pipeline — free account, 30 seconds.
Indoco Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹520 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indoco Remedies Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Sudeep Pharma Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations:** Rs 196.7 crore . Key investor presentation takeaways from Sudeep Pharma Ltd's Q2 FY27 investor presentation — and how it rank
- Jagsonpal Pharmaceuticals Ltd (Q2 FY27)
Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY . Key investor presentation takeaways from Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation — and
- Zota Health Care Ltd (Q2 FY27)
Revenue from Operations for Q2FY27 is ₹19,933.14 lakhs, up 54.58% YoY from ₹12,894.82 lakhs in Q2FY26. Key investor presentation takeaways from Zota Health Care
- FDC (Q2 FY27)
47,303 lakhs in Q2 September 2025 (approximately 20.9% YoY growth). Key results statement takeaways from FDC Ltd's Q2 FY27 results statement — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Indoco Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indoco Remedies Ltd Q2 FY27 results?
Consolidated revenues for Q2 FY 2026-27 are ₹5,069 million, up 7.4% year-on-year (YoY) from ₹4,718 million in the same quarter last year. Quarter ended 30.09.2026: - However, Revenue from Operations is ₹50,692 Lakhs and Expenses total ₹53,509 Lakhs, indicating an operating loss.
What is Indoco Remedies Ltd share price analysis?
Indoco Remedies Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,034 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Indoco Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.